| Diabetes area participation analysis: a review of companies and targets described in the 2008 - 2010 patent literature. | |
| | |
MedLine Citation:
|
PMID: 21083519 Owner: NLM Status: In-Process |
Abstract/OtherAbstract:
|
IMPORTANCE OF THE FIELD: Type 2 diabetes is a chronic disease characterized by the development of insulin resistance, impaired pancreatic β-cell function and, ultimately, hyperglycemia. The disease is highly associated with obesity and it is thought that the inappropriate deposition of lipid in tissues such as liver and muscle contributes to a reduction in insulin sensitivity which, in turn, places a burden on the β-cell to secrete more insulin to achieve normoglycemia. Over an extended period of time, this can result in β-cell failure and diminished glycemic control. When poorly managed, type 2 diabetes increases the risk of developing both microvascular and macrovascular complications, including retinopathy, nephropathy and coronary artery disease. The number of Americans with diabetes has approached 24 million in 2007 and the prevalence of the disease is projected to increase with the sedentary lifestyles and high caloric diets that are common today. First-line treatment for the disease involves lifestyle modifications and, if unsuccessful, pharmacotherapy to control symptoms. Anti-diabetic drugs belonging to several mechanistic classes are available (e.g., insulin secretagogues, insulin sensitizers, insulin mimetics and DPP IV inhibitors); however, many of these drugs lose their effectiveness over time, are not well-tolerated in some patients or may have suboptimal risk:benefit ratios. The search for new anti-diabetic drugs has continued to attract considerable interest from both academia and the pharmaceutical industry. AREAS COVERED IN THIS REVIEW: An analysis of 2008 - 2010 patent applications claiming diabetes as an indication has been undertaken. WHAT THE READER WILL GAIN: An understanding of: i) the pharmaceutical companies that have filed patent applications in the anti-diabetes area during 2008 - 2010; ii) the different pharmacological targets under investigation and the patent activity around such targets; iii) some of the targets in the research portfolios of selected companies; iv) chemical structures of compounds that modulate emerging targets and v) the pharmacological rationale underlying several targets with the largest patent counts. TAKE HOME MESSAGE: Type 2 diabetes is a complex disease with many potential points of intervention for pharmacotherapy. A majority of anti-diabetic patent applications claim chemical matter for just eight targets which include five enzymes, a GPCR, a family of nuclear hormone receptors and a class of sodium-dependent glucose co-transporters (11β-HSD1, DGAT1, DPP IV, glucokinase, GPR119, PPAR-α, -δ, -γ, SGLT1 and SGLT2, and stearoyl-CoA desaturase 1 (SCD1)). The major pharmaceutical companies are all pursuing some combination of these top eight targets. Several companies stand out for the breadth of new targets under investigation (e.g., F. Hoffmann-La Roche, Merck & Co., Pfizer, Takeda Pharmaceuticals, Sanofi-Aventis). |
| | |
Authors:
|
Philip A Carpino; Bryan Goodwin |
Related Documents
:
|
15829899 - New approaches in the intensive management of cardiovascular risk in the metabolic synd... 20191079 - Impact of data from recent clinical trials on strategies for treating patients with typ... 15063599 - Diabetes care and complications in a remote primary health care setting. 18804209 - Increased levels of endothelial microparticles cd144 (ve-cadherin) positives in type 2 ... 10782749 - Calcium channel blockers in diabetic subjects: innocent at last? 9686919 - Incidence of cardiovascular disease in type 1 (insulin-dependent) diabetic subjects wit... 21435929 - Trends in the quality of care for elderly people with type 2 diabetes: the need for imp... 11114099 - Insulin receptors and insulin actions in the nervous system. 21731609 - Body mass index and diabetes in asia: a cross-sectional pooled analysis of 900,000 indi... |
Publication Detail:
|
Type: Journal Article |
Journal Detail:
|
Title: Expert opinion on therapeutic patents Volume: 20 ISSN: 1744-7674 ISO Abbreviation: Expert Opin Ther Pat Publication Date: 2010 Dec |
Date Detail:
|
Created Date: 2010-11-18 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9516419 Medline TA: Expert Opin Ther Pat Country: England |
Other Details:
|
Languages: eng Pagination: 1627-51 Citation Subset: IM |
Affiliation:
|
Pfizer PharmaTherapeutics, MS8220-2105, Groton, CT 06340, USA. Philip.a.carpino@pfizer.com |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Prevalence of antimicrobial resistance among Salmonella isolates from chicken in China.
Next Document: Targeting survivin in cancer: patent review.